| Literature DB >> 29673923 |
Tianzuo Zhan1, Niklas Rindtorff2, Johannes Betge1, Matthias P Ebert3, Michael Boutros4.
Abstract
CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer.Entities:
Keywords: CRISPR; Cancer; Cas9; Genome-engineering; High-throughput screening; Immune therapy; Organoids; Synthetic lethality
Mesh:
Year: 2018 PMID: 29673923 DOI: 10.1016/j.semcancer.2018.04.001
Source DB: PubMed Journal: Semin Cancer Biol ISSN: 1044-579X Impact factor: 15.707